Berman Nathaniel, Reid M Carrington, Teresi Jeanne, Eimicke Joseph P, Adelman Ronald
1 Division of Nephrology and Hypertension, Weill Cornell Medical College , New York, New York.
2 The Rogosin Institute , New York, New York.
J Palliat Med. 2016 May;19(5):503-8. doi: 10.1089/jpm.2015.0338.
An increasing proportion of hemodialysis patients are ineligible for transplant. Often these patients are elderly, with multiple comorbidities and decreased functional status. Such patients may benefit from modified treatment goals to reduce symptom burden.
To demonstrate the feasibility of a trial of reduced-intensity treatment in nontransplantable patients with end-stage renal disease (ESRD).
A 6-week study randomized patients to a reduced-intensity intervention versus usual care. Intervention subjects were treated with liberalized goals for serum phosphorus and parathyroid hormone (PTH) as well as predialysis blood pressure in comparison with usual care subjects. Outcomes included assessed feasibility of recruitment, randomization, and data collection.
Sixteen transplant-ineligible hemodialysis patients were recruited from two urban units.
Blood pressure was recorded weekly, while serum PTH and phosphorus were assessed every 10 days. A quality-of-life measure was administered before and after the trial.
Of 300 patients, 51 were eligible and 16 consented. All were randomized and completed the trial. Patients in the intervention group received significantly lower doses of phosphorus binders and vitamin D analogues, and were less likely to have their dry weight reduced. All patient surveys were completed.
High-risk hemodialysis patients may benefit from liberalized treatment guidelines but larger studies are necessary.
越来越多的血液透析患者不符合移植条件。这些患者通常年事已高,合并多种疾病,功能状态下降。这类患者可能会从调整治疗目标以减轻症状负担中获益。
证明在不可移植的终末期肾病(ESRD)患者中进行低强度治疗试验的可行性。
一项为期6周的研究,将患者随机分为低强度干预组和常规治疗组。与常规治疗组相比,干预组患者在血清磷、甲状旁腺激素(PTH)以及透析前血压方面采用更宽松的目标进行治疗。结果包括评估招募、随机分组和数据收集的可行性。
从两个城市单位招募了16名不符合移植条件的血液透析患者。
每周记录血压,每10天评估血清PTH和磷水平。在试验前后进行生活质量测量。
300名患者中,51名符合条件,16名同意参加。所有患者均被随机分组并完成试验。干预组患者接受的磷结合剂和维生素D类似物剂量显著较低,且体重减轻的可能性较小。所有患者调查均已完成。
高危血液透析患者可能会从更宽松的治疗指南中获益,但需要进行更大规模的研究。